- Home
- DGICA vs GERN Comparison
DGICA vs GERN Comparison
Compare DGICA & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DGICA
- GERN
- Stock Information
- Founded
- DGICA 1986
- GERN 1990
- Country
- DGICA United States
- GERN United States
- Employees
- DGICA N/A
- GERN N/A
- Industry
- DGICA Property-Casualty Insurers
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- DGICA Finance
- GERN Health Care
- Exchange
- DGICA Nasdaq
- GERN Nasdaq
- Market Cap
- DGICA 705.0M
- GERN 740.5M
- IPO Year
- DGICA N/A
- GERN 1996
- Fundamental
- Price
- DGICA $20.00
- GERN $1.12
- Analyst Decision
- DGICA Hold
- GERN Buy
- Analyst Count
- DGICA 1
- GERN 7
- Target Price
- DGICA $18.00
- GERN $3.00
- AVG Volume (30 Days)
- DGICA 110.3K
- GERN 8.6M
- Earning Date
- DGICA 10-30-2025
- GERN 11-05-2025
- Dividend Yield
- DGICA 3.65%
- GERN N/A
- EPS Growth
- DGICA 219.91
- GERN N/A
- EPS
- DGICA 2.38
- GERN N/A
- Revenue
- DGICA $987,826,105.00
- GERN $183,403,000.00
- Revenue This Year
- DGICA $2.26
- GERN $166.20
- Revenue Next Year
- DGICA $3.46
- GERN $55.83
- P/E Ratio
- DGICA $8.39
- GERN N/A
- Revenue Growth
- DGICA 0.89
- GERN 522.13
- 52 Week Low
- DGICA $14.17
- GERN $1.04
- 52 Week High
- DGICA $21.12
- GERN $4.21
- Technical
- Relative Strength Index (RSI)
- DGICA 64.30
- GERN 40.96
- Support Level
- DGICA $19.42
- GERN $1.04
- Resistance Level
- DGICA $20.00
- GERN $1.28
- Average True Range (ATR)
- DGICA 0.48
- GERN 0.07
- MACD
- DGICA 0.12
- GERN 0.00
- Stochastic Oscillator
- DGICA 97.53
- GERN 30.12
About DGICA Donegal Group Inc.
Donegal Group Inc is an insurance holding company that offers businesses and individuals personal and commercial lines of property and casualty insurance. The company's reportable segments are its Investment function, Personal lines of insurance, and Commercial lines of insurance. Personal lines products consist mainly of homeowners and private passenger automobile policies. The Commercial lines products of its insurance subsidiaries consist mainly of commercial automobile, commercial multi-peril, and workers' compensation policies. The group mainly operates in the United States.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.